The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Have lockdown heroes lost their superpower?

Wed, 21st Oct 2020 13:17

* European stocks fall for second straight session

* Centamin shares down 20% after production update

* Construction sector dips 1.6%, real estate down 1.7%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

HAVE LOCKDOWN HEROES LOST THEIR SUPERPOWER? (1215 GMT)

Some companies have had a stellar performance during the spring lockdown with shares in the
so-called WFH (Working from home) stocks, like food delivery companies and software developers,
rising beautifully.

Yet, as governments across Europe announce stricter restrictions, names like Hello Fresh
(+167% YTD), Delivery Hero (+38%), Sinch (+190%), TeamViewer (+30%) or Ocado (+87%) have failed
to impress this time around.

Why?

"The increase in the customer base for some of those companies perhaps has already been
priced in," says Connor Campbell at Spreadex. "So, new restrictions, don't necessarily mean we
are going to see an increase in business for those kinds of companies".

Joshua Mahony, at IG, says markets are preferring to look towards value stocks as, with
hopes for a vaccine, they think the worst is behind us. "It does feel as though we are entering
the final stretch".

Airlines and other hard-hit stocks are gaining ground over those WFH stocks, he says.

"One thing we have seen throughout this crisis is the willingness to look through the here
and now to reflect where things might be at the next stage of the crisis".

Deutsche Bank analysts reiterate their buy on Hello Fresh and Delivery Hero.

"We think a one day of sell-off (if sell-off could be called a 2-3% negative share price
reaction) does not change the fundamental positive trajectory of the groups", they say.

(Joice Alves)

*****

MESSY MARKETS! WHAT TO BUY? (1128 GMT)

A vaccine approval, shorter/less-strict social restrictions, coupled with a strong economic
growth, a moderate rise in inflation rates and a weak dollar are possibilities to look forward
to in 2021.

And, if this materializes, Credit Suisse analysts have some ideas:

- European renewables, as wind capacity is expected to rise by 15-fold in the next 20 years
and the carbon price to be at $100 ton by 2030; besides grids deserve un upgrade, including RWE
, EDP,, National Grid

- Mining stocks, thanks to Chinese infrastructure investments seen remaining strong. CS
analysts highlight Anglo American.

- Construction materials, as U.S. housing is set to grow 20% on very low bond yields and
governments are focused on infrastructure. They “like stocks exposed to insulation.”

- China tech, as P/E relatives are at 15-year lows while earnings revisions remain very
strong and there are “all the ingredients of a bubble that has yet to really start.”

- Defence, as spending will grow in a tri-polar world and telecom equipment with 5G a
superfast broadband seen as a necessity. CS says U.S. valuations in defence sector at 20-year
lows, with BAE “looking abnormally cheap.”

(Stefano Rebaudo)

*****

WHEN WILL UK DIVIDENDS BOUNCE BACK TO PRE-PANDEMIC LEVELS? (0900 GMT)

It's anyone's guess!

Link Group says the best case scenario is a recovery to 2012-13 levels in 2021.

UK dividends have recovered a tad from the depths of last quarter but they still had the
lowest third quarter in ten years, leaving investors eager to find out how much they will wait
to see payouts levels bouncing back.

Underlying dividends, which exclude special payments, fell 45.1% to £17.7bn in Q3, according
to Link Group.

"Though by any normal standards a fall of this magnitude is terrible for investors, it is
significantly better than the 57.2% drop in the second quarter," it says.

Link Group adds that investors will likely only see dividends recovering by March 2021 and
it pencils in a best-case increase of 15% and a worst case of 6% for next year.

"The fourth quarter this year and the first quarter next are set for further sharp declines,
but from April onwards, the anniversary of the lockdown, the comparisons will start to look more
favourable and we expect to see a bounce-back begin".

(Joice Alves)

******

EUROPEAN STOCKS HEAD LOWER (0800 GMT)

European stocks dipped for the second straight day dragged down by construction, healthcare
and oil outweighing a decent batch of better-than-expected Q3 results.

The STOXX 600 is down 0.6%, with the construction sector leading the losses.

In terms of single stocks, Shares in Ericsson are up 7%, after quarterly core
earnings beat market estimates and the company says it is "more confident" in meeting its 2020
targets.

Mining company Centamin's shares fell to the bottom of the pan European index, down
18% after the company’s production update.

Shares in Iberdrola are down 0.6%, after the company issued results and announced
its U.S. unit Avangrid agreed to buy U.S. utility PNM Resources for around $4.3
billion.

(Stefano Rebaudo and Joice Alves)

*****

ON THE RADAR: IBERDROLA UNIT MERGER, AKZO NOBEL, ERICSSON (0639 GMT)

European stocks are poised to open higher, with sentiment boosted by hopes for a U.S. rescue
package and better-than-feared earnings results.

While concerns about the pandemic in Europe continue to weigh, we have a decent batch of
corporate news to cheer up investors, starting with a multi-billion cross border merger in the
renewable energy sector. Avangrid, the U.S. unit of Iberdrola, has agreed to
buy U.S. utility PNM Resources for around $4.3 billion. The merged company would have
assets worth $40 billion and generate core earnings of around $2.5 billion and net profit of
$850 million.

Akzo Nobel reports a better-than-expected 18% increase in third-quarter core
profit to 353 million euros.

Nestle stocks are up 2.7% in premarket trade after the company beats Q3 sales
expectations and raises its guidance for 2020.

Ericsson quarterly core earnings beat market estimates, helped by higher margins
and China's 5G rollout, and is "more confident" in meeting its 2020 targets.

Good news also on the vaccine front as AstraZeneca Plc's trial in the United States
is expected to resume as early as this week after the U.S. Food and Drug Administration
completed its review of a serious illness in a study participant.

But we still see pressure on the financial sector. Shares in GAM Holding are down
2.2% in premarket trade after results., while Handelsbanken reports
lower-than-expected quarterly net earnings due to restructuring costs.

Vinci expects earnings to continue falling in the second half of the year, as
weakness at its pandemic-ravaged airports business outweighs signs of a recovery in construction
and motorway traffic.

GlaxoSmithKline would move its experimental vaccine against the respiratory
syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of
testing, encouraged by mid-stage trial results.

Shares in Bilfinger are up 7.2% after press reports on possible takeover of the
company.

(Stefano Rebaudo)

*****

EUROPE CAUTIOUSLY IN THE BLACK (0528 GMT)

European stock futures are in the black along with their U.S. peers as hopes of a quick
approval of a U.S. stimulus package are propping up risk sentiment.

But investors continue to be cautious as coronavirus trajectories as well as possible new
restrictive measures are now seen as the single biggest near-term risk to the economic recovery.

Italy, Spain and Britain are considering new restrictions, including curfew in hard-hit
regions, to limit the spread of the pandemic. The latest curbs in Ireland will see GDP fall by
3.5% this year, Finance Minister Paschal Donohoe said.

(Stefano Rebaudo)

*****

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.